All About Flavay®
Flavay Plus®
What Does it Do?
Q&A
Accept No Substitutes
Comparative Analysis
Endorsements & Testimonials
Proven Safety
Directions for Use
Contact Us
Free Research Brochure
Order Now

Flavay® Restores Sticky Blood Platelets to Normal

When we are under stress, our adrenaline flows and causes our blood vessels to constrict, increasing blood pressure, and blood platelets are activated—prepared to clump together to form a clot. This "fight or flight response" is appropriate in short-term dangerous situations. The blood platelets are prepared for an injury to more quickly form a blood clot and more efficiently prevent blood loss.

Chronic stress causes constant constriction of blood vessels and continuously "sticky" blood platelets, always prepared to form a clot. These are classic risk factors for heart disease and stroke. When blood vessels are constricted there is less area for the blood to flow through and atherosclerotic plaque may further reduce the space for blood flow. If some blood platelets stick together and form a clot, the vessel may be completely clogged and surrounding tissue is deprived of oxygen and nutrients. This is how a heart attacks and strokes develop.

Research shows that Flavay® improves nitric oxide levels produced by cells that line the arteries. Nitric oxide controls the muscles surrounding the blood vessels and causes them to relax. At the same time, nitric oxide causes blood platelets to return to their normal, smooth condition.

Flavay® inhibits platelet aggregation by inhibiting the enzymes thromboxane A2, 5-lipoxygenase and other clotting compounds. The good news is that Flavay® protects the blood platelets without an increased risk of bleeding and other common side effects of aspirin.

Aspirin is widely prescribed by doctors to prevent heart attacks because of its ability to inhibit platelet aggregation by inhibiting the enzyme cyclooxygenase. However, Flavay® works differently. Flavay® supports the body's own production of nitric oxide—helping the body to produce adequate levels and thereby causing the blood platelets to return to their normal, smooth condition.

Flavay® and the Nitric Oxide Connection

Nitric oxide is a colorless gas produced by different cells in the body that, depending on the situation, can be very good or very bad. Nitric oxide plays several important roles in the body:

• Nitric oxide is an important signaling molecule that turns genes on and off.
  
• By controlling the muscular tone of blood vessels, nitric oxide regulates the circulation and normalizes blood flow.
  
• Nitric oxide modulates communication between brain cells and is instrumental in helping us concentrate and learn new information, and also in maintaining memory.
  
• When produced by immune cells, nitric oxide fights infection, kills tumor cells and promotes wound healing.
  
• Nitric oxide is essential for perceiving pleasure and pain, and it helps translate sexual excitement into penile erections.
  
• Nitric oxide aids in digestion of food by helping to control gastric movements.

But nitric oxide can be very destructive under other circumstances:

• Nitric oxide restricts blood flow.
  
• When produced in excess by immune cells, nitric oxide can trigger chronic inflammation, which can cause arthritis, colitis, inflammatory bowel disease and possibly cancer.
  
• Nitric oxide promotes production of more free radicals.
  
• In the brain, nitric oxide can hamper mental function and cause memory loss and brain aging.

The real trouble starts when nitric oxide encounters the superoxide free radical and becomes peroxynitrate, which destroys antioxidants like glutathione, vitamin E and common flavonoids, and damages proteins in the body. The good news is that Flavay® scavenges peroxynitrate and has a remarkable modulatory effect on nitric oxide—helping to maintain optimal levels in the body and neutralizing this free radical where it does harm.

"Radical Scavenger Effect" of Flavay®
Protected by U.S. Patent No. 4,698,360

Patented and licensed in France for therapeutic uses, the U.S. Government granted Dr. Masquelier a patent on October 6, 1987 which allows his proanthocyanidins complex, now sold as Flavay®, to be used as an antioxidant here in the United States.

Flavay® is the product—used in the actual experiments—by which Dr. Jack Masquelier established and patented the "radical scavenger effect."

Flavay® has been sold world-wide for cardiovascular health and extensively tested in humans for more than 50 years. The vascular protective activity of Flavay® has been established by many significant studies, demonstrating several important ways in which Flavay® may mitigate the risk of heart attack and stroke. [More...]

CLICK HERE FOR AN INDEPENDENT LAB REPORT
CLICK HERE TO PURCHASE NOW

Masquelier, J. Plant extract with a proanthocyanidins content as a therapeutic agent having radical scavenging effect and use thereof. U.S. Patent No. 4,698,360, 1987.
Masquelier, J. A lifetime devoted to OPC and Pycnogenols. Alfa Omega Editrice, Pub., 1996.
Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega Editrice, Publishers, 1995.
Lombard, J., Germano, C. The brain wellness plan: breakthrough medical, nutritional and immune-boosting therapies to prevent and treat: depression, Alzheimer's disease, chronic fatigue syndrome, attention deficit disorder, multiple sclerosis, Parkinson's disease, Lou Gehrig's disease. Kensington Pub. Corp., 1998.
Kilham, C., Masquelier, J. OPC: The miracle antioxidant. Keats Publishing, Inc., 1997.
Packer, L., et al. The antioxidant miracle: your complete plan. John Wiley & Sons, Inc., 1999.
Packer, L., et al. Antioxidant food supplements in human health. Academic Press, 1999.
Lincoln, J., Hoyle, C.H.V., Burnstock, G., Nitric oxide in health and disease. Cambridge University Press, 1997.
Moncada, S., Nistico, G., Bagetta, G., Higgs, E.A. Nitric oxide and the cell. Princeton University Press, 1998.
Facino, R.M., et al. Free radical scavenging action and anti-enzyme activities of procyanidines from vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44: 592-601, 1994.
Passwater, R.A. The antioxidants: the nutrients that guard your body. Keats Publishing, Inc., 1985.
Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants. Keats Publishing, Inc., 1995.
Facino RM, et al. Free radical scavenging action and anti-enzyme activities of procyanidines from Vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44: 592-601, 1994.
Kuttan R, et al. Collagen treated with catechin becomes resistant to the action of mammalian collagenase. Experientia, 37: 221-223, 1981.
Masquelier, J., et al. Stabilization du collagene par les oligomeres procyanidoliques. Acta Therapeutica, 7:101-105, 1981.
Masquelier, J. Aspects pharmacologiques nouveaux de certains flavonoides. A Vie Medical 12:1969.
Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques totaux du raisin. Acta Therapeutica, 4, 1978.
Laparra, J., et al. Etude pharmacocinetique des oligomeres flavonoliques. Plantes med et phyto, Tome XI, pp. 133-142, 1977.
Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de l’action des oligomeres procyanidoliques sur des cellules mesenchymateuses en culture. Ii l’attachment des fibres elastiques aux cellules. (Study of the effect of procyanidolic oligomers on mesenchymal cells in culture. Ii attachment of elastic fibers to the cells.) Pat Biol, (30)6:601-7, 1990.
Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular and crystal structure of (+)-2,3-trans-3,4-trans-leucocyanidin [(2r,3s,+r)-(+)-3,3’, 4.4’, 5.7’-Hexahydroxyflavan] dihydrate, and comparison of its heterocyclic ring conformation in solution and the solid state. Journal of the Chemical Society; Perkin Transactions I 1985. pp. 1413-17.
Masquelier, J. Proanthocyanidins et radicaux libres. 1985.
Uchida, S., et al. Condensed tannins scavenge active oxygen free radicals. Med Sci Res, (15) 1987. pp. 831-832.
Ariga, T. Radical scavenging action and its mode in procyanidins b-1 and b-3 from azuki beans to peroxyl radicals. Agric Biol Chem, 54(10) 1990. pp. 2499-2504.
Da Silva, R., et. al. Radical scavenger capacity of different procyanidins from grape seeds. Presented at a symposium, “Free radicals in biotechnology and medicine.” Royal Society Of Chemistry, London January 1990, pp. 79-80.
Bauman, J., Wurm, G., Bruchhausen, F. “Hemmung der prostagladinsynthetase durch flavonoide und phenolderivate im vergleich nit deren 02 radikalfangereigenschaften” Arch Pharm, (Weinheim) 313 (1980) pp. 330-337.
Flesch M., et al., Effects of red and white wine on endothelium-dependent vasorelaxation of rat aorta and human coronary arteries. Am J Physiol 1998;275:1183-94.
Fitzpatrick, D.F., Fleming R.C., Bing B, Maggi DA, O'Malley RM. Isolation and characterization of endothelium-dependent vasorelaxing compounds from grape seeds. J Agr & Food Chem In press.
Fitzpatrick, D.F., Maggi D, Bing B, Coffey RG. Vasorelaxation, endothelium, and wine. BioFactors 1997;6:455-459.
Fitzpatrick, D.F., Hirschfield SL, Ricci T, Jantzen P, Coffey RG. Endothelium-dependent vasorelaxation caused by various plant extracts. J Cardiovasc Pharmacol 1995;26:90-95.
Fitzpatrick, D.F., Hirschfield SL, Coffey RG. Endothelium-dependent vasorelaxing activity of wine and other grape products. Amer J Physiol 1993;265:H774-H778.
Kuttan, R., Donnelly, P.V., Di Ferrante, N. Collagen treated with catechin becomes resistant to the action of mammalian collagenase. Experientia, 37: 221-223, 1981.
Masquelier, J. Procyanidolic oligomers. J Parums Cosm Arom, 95: 89-97, 1990.
Tixier, J.M., et al. Evidence by in vivo and in vitro studies that binding of pycnogenols to elastin affects its rate of degradation by elastases. Biochem Pharmacol, 33: 3933-3939, 1984.
Kakegawa, H., et al. Chem. Pharm. Bull. 33:5079, 1985.
Harmand, M.F., Blanquet, P. The fate of total flavanolic oligomers extracted from ‘vitus vinifera l.’ in the rat. European Journal of Drug Metabolism and Pharmaccokinetics. 1978, No. 1 pp. 15-30.
Delrieu, P., Ding J., Escande, B., Samain, D. Free-radical scavenging activity of proanthocyanidolic oligomers encapsulated in glycospheres: an in vivo and in vitro study. Cosmetology Department & S Biovectors, Ramonville St. Agne France. pp. 1-9.
Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i converting enzyme by flavanolic compounds: in vitro and in vivo studies. Planta Medica, May 26, 1986. pp. 12-15.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques chez l’animal-oedenme de la patte. Sanofi Res Toul Cedex Fr, pp31-40.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques chez l’animal-activite aniagoniste vis-a-vis des mediateurs de l’inflamation. Sanofi Res Toul Cedex Fr, pp. 31-40.
Dubos, C., Durst, G., Hugonot, H. Evolution de la resistance capillaire, spontanement ou artificiellement diminuee par l’action d’une substance capillaro-toxique chez des personnes agees--action benefique d’un agnet actif sur la micro-circulation: l’Endotelon. Inform. Therapeut. 1980. pp. 302-305.
Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude d’un microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7, 1990.
Lagrue, G., Olivier-Martin, F., Grillot, A. “Etude des effets des oligomeres du procyanidol sur las resistance capillaire dand l’hypertension arterielle et certaines nephropathies.” Sen. Hosp. Paris 18-25 Septembre, 1981.
Beylot, C., Bioulac, P. Essai therapeutique d’un angioprotecteur peripherique, l’Endotelon. Actualite Therapeutique Gaz. Med. de France (87)22:2919-24, 1980.
Lesbre, F.X., Tigaud, J.D. Effect de l’Endotelon sur l’indice de fragilite capillaire dan une population specifique: les sujets cirrhotiques. Gaz. Med. de France, (90)24 1983.
Sarrat, L. Abord therapeutique des troubles fonctionnels des membres inferieurs par un microangioprotecteur l’Endotelon. Bordeaux Med, 11:685-8, 1981.
Delacroix, P. Etude en double aveugle de l’Endotelon dans l’insuffisance veineuse chronique. Therapeutique, la Revue de Medicine, (27-28) Sept. 1981. pp. 1793-1802.
Thebaut, J.F, Thebaut, P., Vin, F. Etude de l’Endotelon dand les manifestations fonctionnelles de l’insuffisance veineuse peripherique-resultats d’une etude en double aveugle portant sur 92 patients.” Gazette Medicale, (92)1, 1985. pp. 96-100.
Wegrowski, J., Robert, A.M., Maczar, M. The effect of procyanidolic oligomers on the composition of normal and hypercholesterolemic rabbit aortas. Biochem. Pharmacol, (33)21. 1984. pp. 3491-3497.
Chang, W.C., Hsu, F.L. Inhibition of platelet aggregation and arachidonate metabolism in platelets by procyanidins. Prostagland Leukotri Essent Fatty Acids, 38:181-8, 1989.
Masquelier, J. Pycnogenols: recent advances in the therapeutical activity of procyanidins. Supplement of Planta Medica, Journal of Medicinal Plant Research and Journal of Natural Products, July 1980 pp. 243-256.
Henning, B., et al. Lipid peroxidation and endothelial cell injury: implications in atherosclerosis. Free Rad Path & Med, (4)1988 pp. 99-106.
Masquelier, J. “Les procyanidols du vin leur role dans l’alcoolisme.” pp. 88-93.
Gazave, J.M. “Notions recentes sur les capillaires” unpub. bulletin from the Laboratoire De Physiologie Patholigie pp. 26-29.
Ruf, J.C. Wine and polyphenols related to platelet aggregation and atherothrombosis. Office International Vigne et du Vin, Nutrition and Health Unit, Paris France; Drugs under Experimental and Clinical Research (Switz.) 25/2-3 (125-131), 1999.
Blaszo, G. Gabor, M. Oedema-inhibiting effect of procyanidin. Acta Physiologica Academiae Scientiarum Hungaricae, Tomus 56(2):235-240, 1980.
Tayau, M.F, LeFevre, G. Action du leucocyanidol sur l’hyalaluronidase. Bull Soc Pharm Bordeaux, 95:132-136, 1956.
Lamy, M. Utilization des oligomeres procyanidoliques en gynecologie. Essai Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
Henriet, J.P “Une Etude Exemplaire Pour Un Phlebotrope: l’etude EIVE.’ Unpub., pp. 77-83.
Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres procyanidoliques dans la paroi des capillaires sanguins du poumon decobaye. Acta Therapeutica (8) 1982. pp. 223-237.
Kuttan, R., Donnelly, P., Di Ferrante, N. “Collagen treated with (+) -catechin becomes resistant to the action of mammalian collagenase.” Laboratory of Connective Tissue Research, Dept. of Biochem. Baylor Col. of Med., Houston TX. 28, May, 1980.
Gendre, P., Laparra, J., Barraud, E. “Effect protecteur des oligomeres procyanidoliques sur le lathyrisme experimental chez le rat.” Ann. Pharm. Francaises, (43)1, 1985 pp. 61-73.
Corbe, C., Boissin, J.P., Siou, A. Light vision and chorioretinal circulation. Study of the effect of procyanidolic oligomer (Endotelon). Jn. Fr. Opthalmol, (11)5:453-460, 1988.
Boissin, J.P., Corbe C., Siou, A. Chorioretinal circulation and dazzling: use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol Fr, 88(2):173-4, 177-9, 1988.
Proto, F. et al. Electrophysical study of vitis vinifera procyanoside oligomers effects on retinal function in myopic subjects. Ann Ott Clin Ocul, 114:85-93, 1988.
Saracco, J.B., Estachy, G.M. Etude d l’Endotelon en opthalmologie. Gaz Med de France, 88:2035-2038, 1981.
Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies. Klin Monatsbl Augenheilkd, 178:386-389, 1981.
Corbe, C., et al. Microangiopathy of the retina. J. Fr. Opthalmol, 11:453, 1988.
Verin, M.M., Vildy, A., Maurin, J.F., Retinopathies et O.P.C. Bordeaux Medicale, (16)11. pp. 1467-74, 1978.
Soyeux, A. et al. Endotelon. Diabetic retinopathy and hemorheology. Bull Soc Ophtalmol Fr. 87(12):1441-4, 1987.
Fromantin, M. “Les oligomeres procyanidoliques dans le traitement de la fragilite capillaire et de la retinopathie chez les diabetiques. A propos de 26 cas.” Med Int, 16(11):432-434, Nov. 1981.
Arne, J.L. Contribution a l’etude des oligomeres procyanidoliques: Endotelon, dans la retinopathie diabetique (a propos de 30 observations). Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
Baruch, J. Effect of Endotelon in postoperative edema. Results of a double-blind study versus placebo in 32 female patients. Ann Chir Plast Esthet 29(4):393-5, 1984.
Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism in rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62, 1981.
Gabor, M. Pharmacologic effects of flavonoids on blood vessels. Angiologica, 9:355-374, 1972.
Havsteen, B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol, 32:1141-48, 1983.
Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer, H.J. Berkhauser Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger., 1977.
Masquelier, J. Action protectrice du vin sur l’ulcere gastrique. Resultats, p. 61.
Amella, M., et al. Inhibition of mast cell histamine release by flavonoids and bioflavonoids. Planta Medica, 5116-20, 1985.
Shaw, R. How [Australian] PycnoGenol [MASQUELIER’s®] Helps Sports People.
Masquelier, J. Procyanidolic oligomers (leucocyanidins). Parfums Cosmet Arom 95:89-97, 1990.
Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques (Endotelon) dans le traitement des lymphoedemes post-therepeutiques de members superieurs. Symposium Satellite, Congres International d’Angiologie, Toulouse, France, 4-7 Oct. 1989.